Hypoxia and Oxygen-Sensing Pathway Modulation
Certainty: 0.45. Brief controlled hypoxic exposures may induce beneficial HIF-1\(\alpha\)-dependent adaptations including mitochondrial biogenesis, angiogenesis, and metabolic efficiency (Gangwar et al. 2019). IHT has shown promise in Parkinson’s disease (Janssen Daalen et al. 2025) and in athletic conditioning. The ME/CFS adaptation requires: supine position (eliminates orthostatic stress), mild hypoxia (FiO2 0.16, equivalent to 2000m), short cycles (3–5~min hypoxia alternating with 3~min normoxia, total 30~min), and strict PEM monitoring (48~h post-session).
Mechanistic rationale. Brief hypoxia → HIF-1\(\alpha\) stabilization → transcriptional programme activation → VEGF (angiogenesis), EPO (erythropoiesis), PGC-1\(\alpha\) (mitochondrial biogenesis), GLUT1 (glycolytic capacity). Repeated sessions are hypothesised to raise the hypoxic threshold and improve exercise tolerance.
Safety. Potential PEM trigger if protocol exceeds individual tolerance — requires graduated introduction (start FiO2 0.19, decrease 0.01 per week). Contraindicated in severe ME/CFS (bedbound patients), uncontrolled POTS, or hemoglobinopathies. Normobaric hypoxia carries no barotrauma risk. Hypoxia-induced vasodilation could worsen orthostatic intolerance in susceptible patients.
Testable prediction. 8 weeks IHT (3 sessions/week) improves 6MWT distance ≥40~m vs sham (FiO2 0.21) in mild-to-moderate ME/CFS, with sustained CBFv during hypoxic cycles.
Certainty: 0.30. IHHT — repeated cycles of hypoxic (FiO2 9–13%) and hyperoxic (FiO2 ~36%) exposure — is distinct from the hypoxia-only IHT above: the alternating hyperoxic restitution phase is hypothesised to enhance mitochondrial antioxidant/repair pathway activation via hormetic redox signalling (Q. Zhang et al. 2023). The registered, blinded, placebo-controlled REenergizeME RCT (Nochi et al. 2026) is testing this in 104 female ME/CFS patients (International Consensus Criteria, mild–moderate NICE) over 6 sessions in 8 weeks, primary endpoint SF-36 vitality (Nochi et al. 2026).
Mechanistic rationale (hypothesis, not established). Recurrent mild hypoxic injury to brain and muscle — from microvascular dysfunction and functional GPCR autoantibodies disrupting oxygen delivery — is hypothesised to contribute to the mitochondrial dysfunction, oxidative stress and inflammation associated with PEM; each step is a candidate, not a confirmed chain. Mild hormetic hypoxia stabilises HIF-1\(\alpha\), activating mitochondrial antioxidant/repair, angiogenesis and vascular regulation pathways. This is the controlled ambulatory instantiation of the altitude/HIF-1\(\alpha\) preconditioning hypothesis in this paper (HIF Pathway Inertia: Failure of Hypoxic Adaptation in ME/CFS, hypoxia-altitude corpus) (Nochi et al. 2026) (Q. Zhang et al. 2023).
Distinction from pathological chronic IH (dose-dependent, not categorical). The mild, brief, low-frequency hormetic IHHT profile is proposed to differ from the pathological sustained intermittent hypoxia of OSA, which produces sustained HIF-1\(\alpha\) elevation, oxidative stress, sympathetic activation and cognitive harm (Erdem et al. 2026). Dose/cycle structure determines the outcome (She et al. 2026) — the hormetic window is the safety-critical boundary (Q. Zhang et al. 2023). However, this is a dose-response bet, not a demonstrated category boundary: no data place IHHT’s specific protocol inside the hormetic window in ME/CFS, and concurrent undiagnosed OSA in the cohort is not excluded (the protocol screens for obstructive lung disease but not sleep-disordered breathing). The protocol’s hypoxic phase uses FiO2 9–13%, but it does not specify the target arterial SpO2 excursion during hypoxia; how far each patient descends toward the pathological pole is therefore unmeasured.
Evidence status — protocol only. Zero direct ME/CFS efficacy data exist. Prior long-COVID IHHT evidence is non-randomized or non-controlled (Doehner2024 open pilot; Kapel2025 non-controlled cohort), and one cohort (Kapel2025) overlaps the REenergizeME team and device with a commercial interest — its effect size underpins the trial’s power calculation (Doehner et al. 2024) (Kapel et al. 2025). The blinded placebo-controlled design is the standard corrective to that conflict, but the COI-derived effect assumption also risks underpowering the trial, which could yield a non-informative (rather than merely uncertain) 2029 result. No blinded sham-controlled IHHT RCT has published; results expected 2029.
Safety. IHHT as administered is reported safe in human studies (transient headache, short-lived fatigue; no serious AEs). No ME/CFS-specific harm data exist; PEM exacerbation is the documented protocol-defined AE. Contraindicated in obstructive lung disease, pneumothorax history, pregnancy, claustrophobia, interfering devices. Bedbound/very-severe excluded from the trial; dose unvalidated in ME/CFS. Research-stage — not a clinical recommendation.
Falsifiable prediction. In the REenergizeME RCT, IHHT will produce a greater SF-36 vitality improvement than sham together with the specific hormetic signature — improved NIRS muscle oxygenation recovery and reduced oxidative-stress markers (not merely subjective vitality gain). A between-group vitality difference WITHOUT these mechanistic changes (consistent with placebo or generic autonomic placebo) does NOT support the hormetic-adaptation mechanism; absence of any between-group difference falsifies it outright. This differs from the hypoxia-only IHT prediction by the added requirement of the hyperoxic-phase-specific redox/antioxidant biomarker response.
Consequence: None yet for patients — IHHT is an unproven registered trial; its value is that a rigorous placebo-controlled result (due 2029) will test whether the hypoxia-hormesis mechanism can be harnessed to treat ME/CFS, and its objective mechanistic endpoints (muscle oxygenation, autonomic, biomarkers) may reveal which patients carry the hypoxia-related pathology.
Severity applicability: mild-moderate only (trial inclusion) and female-only (all participants female, 20–59 y); generalizability to male patients untested. Unknown for severe/very-severe, who are excluded and must not attempt IHHT unsupervised (seek a trial site or await results rather than self-treat).
Evidence type: RCT protocol (Nochi2026); non-randomized/non-controlled long-COVID cohorts (Doehner, Kapel); mechanism review (Zhang2023). Not a completed RCT result in ME/CFS.
Certainty: 0.30. Prolyl hydroxylase domain (PHD) inhibitors stabilize HIF-1\(\alpha\)/2\(\alpha\) by blocking oxygen-dependent degradation, increasing endogenous EPO and erythropoiesis. Roxadustat is approved for anemia of chronic kidney disease; daprodustat is in clinical use. In ME/CFS, low-dose PHD inhibition could restore the hypoxic adaptation programme that appears blunted (see HIF Pathway Inertia hypothesis HIF Pathway Inertia: Failure of Hypoxic Adaptation in ME/CFS). Unlike exogenous EPO, PHD inhibitors upregulate the full HIF transcriptional programme (EPO + VEGF + glycolytic enzymes + mitophagy regulators), potentially producing broader metabolic benefit (Winkler et al. 2004).
CAUTION: + Could exacerbate autoimmunity — HIF-1\(\alpha\) promotes Th17 differentiation and B cell activation (Little et al. 2023) + VEGF elevation from HIF-2\(\alpha\) stabilization could worsen endothelial barrier dysfunction in patients whose HIF-2\(\alpha\) is already pathologically active (Section Immune Complex–Endothelial Injury as a Central Vascular Mechanism) (Ribeiro et al. 2026). This risk is subtype-dependent: patients with elevated baseline VEGF/vWF should not receive PHD inhibitors + Excessive erythropoiesis increases blood viscosity, potentially worsening cerebral hypoperfusion + No ME/CFS safety data exist; all literature is from CKD populations with different baseline physiology
Testable prediction. Low-dose daprodustat (1mg TIW, one-quarter the CKD dose) increases constant-workload cycling time to exhaustion by \(>=30\)% without elevating hematocrit above 45% in ME/CFS patients with blunted hypoxia-challenge EPO response.
Certainty: 0.45. Belzutifan is a selective HIF-2\(\alpha\) inhibitor approved for VHL disease-associated tumors that blocks HIF-2\(\alpha\)/ARNT heterodimerization, preventing transcriptional activation of VEGF, EDN1, and SERPINE1. Ribeiro et al. (2026) (Ribeiro et al. 2026) directly demonstrated that belzutifan rescues endothelial barrier integrity in spike S1-stimulated retinal endothelial cells — the only drug shown to reverse this specific post-viral mechanism. The initial certainty (0.25) has been increased to 0.45 based on convergent supporting evidence: (a) Sales et al. (2026) independently showed that HIF-2\(\alpha\) inhibition (via darunavir) preserves tight junction proteins ZO-1 and occludin in a separate epithelial barrier model (Sales et al. 2026), (b) the NRF2-HIF-2\(\alpha\) axis provides a mechanistic framework for sustained HIF-2\(\alpha\) dominance after NRF2 depletion (Shen et al. 2024) (Y. Zhang et al. 2026), and (c) the general principle of viral HIF-2\(\alpha\) exploitation is supported across multiple virus types (HCV (Couteaudier et al. 2025), RSV (Morris et al. 2025)). However, belzutifan’s brain penetration is unknown — peripheral endothelial improvement is expected, but BBB effects are uncertain.
Mechanistic rationale. SARS-CoV-2 spike protein upregulates HIF-2\(\alpha\) in pulmonary and retinal endothelium, promoting VEGF production, intercellular gap formation, and increased permeability. If a similar mechanism operates in ME/CFS (whether from SARS-CoV-2, EBV, HHV-6, or other viral triggers), HIF-2\(\alpha\) inhibition could restore endothelial barrier integrity. The antiviral signaling protein IRF3 directly regulates HIF-\(\alpha\) cytoplasmic retention — viral infection relieves this retention, linking diverse viral triggers to the same HIF-2\(\alpha\) pathway (Deng et al. 2026).
Selection criteria: Post-viral onset, elevated VEGF/vWF, \(\beta_2\)AR-autoantibody-negative (the ~70% subgroup with no known ED mechanism — Section Immune Complex–Endothelial Injury as a Central Vascular Mechanism).
Dosing: Start 40~mg daily. Monitor hemoglobin (risk of anemia — HIF-2\(\alpha\) supports renal EPO production), blood pressure, VEGF q2 wks.
CAUTION. HIF-2\(\alpha\) is not HIF-1\(\alpha\) — the isoforms have distinct, sometimes opposing functions. HIF-2 inhibition could paradoxically worsen hypoxia sensing. HIF-2\(\alpha\) supports erythropoietin production in adults; its inhibition could cause anemia (15–20% incidence in VHL trials). No ME/CFS data exist. Contraindicated in pregnancy.
Testable prediction. 8 weeks belzutifan 40~mg daily reduces VWF antigen (endothelial activation marker) by ≥20% and improves 6MWT distance by ≥30~m in post-viral ME/CFS patients with elevated baseline VWF (>150% normal) and \(\beta_2\)AR-autoantibody-negative status. VEGF reduction should precede clinical improvement by 2–4 weeks.
Certainty: 0.40. Darunavir, an HIV protease inhibitor in clinical use since 2006, was recently shown to prevent HIF-2\(\alpha\) activation and preserve tight junction proteins (ZO-1, occludin) in an experimental oesophageal barrier disruption model (Sales et al. 2026). The mechanism is independent of protease inhibition — darunavir directly blocks HIF-2\(\alpha\) transcriptional activity, preventing the VEGF-driven permeability programme. This represents a repurposing opportunity with an established safety track record (20+ years in HIV populations), dramatically lower cost than belzutifan, and known pharmacokinetics.
Mechanistic rationale. HIF-2\(\alpha\) activation drives VEGF production, which induces intercellular gap formation and barrier disruption. Darunavir inhibits HIF-2\(\alpha\) activation, preserving junctional integrity (Sales et al. 2026). If the same HIF-2\(\alpha\) mechanism operates in post-viral ME/CFS endothelial cells, darunavir may provide barrier protection comparable to belzutifan but at a fraction of the cost.
Dosing: Darunavir 600~mg BID boosted with ritonavir 100~mg BID (standard HIV dosing). CYP3A4 interaction profile is well-characterized.
CAUTION. Hepatotoxicity (3–7%), rash, GI intolerance. Drug interactions via CYP3A4: fludrocortisone, midodrine, LDN, mestinon — all substrates or co-metabolised; levels may change substantially. Requires specialist monitoring. Low CNS penetration — peripheral endothelial protection expected; cognitive symptoms may not improve.
Drug interactions with common ME/CFS co-prescriptions: Darunavir/ritonavir is a strong CYP3A4 inhibitor and CYP2D6 inducer. Fludrocortisone: levels may increase (CYP3A4 substrate) — monitor for hypertension, hypokalemia. Midodrine: levels may increase (CYP3A4). LDN: naltrexone is CYP3A4 substrate — levels may increase. Mestinon (pyridostigmine): not CYP3A4-dependent — no interaction. Beta-blockers: metoprolol and propranolol are CYP2D6 substrates — levels may decrease. Antihistamines: fexofenadine is not CYP3A4-dependent — no interaction; loratadine is CYP3A4 substrate — levels may increase.
Contraindications for bedbound patients: Hepatotoxicity risk requires regular LFT monitoring. GI intolerance may worsen malnutrition risk. Drug interactions are substantial — polypharmacy in bedbound patients requires careful review.
Testable prediction. 4 weeks darunavir/ritonavir in post-viral ME/CFS reduces plasma VEGF and vWF by ≥25% and improves FMD compared to placebo in a double-blind, randomised crossover trial (n=20).
Certainty: 0.40. A standardized hypoxia challenge with serial EPO measurement could serve as a dynamic functional test of HIF pathway integrity in ME/CFS, analogous to the ACTH stimulation test for adrenal insufficiency (Winkler et al. 2004).
Protocol. 2~h mild hypoxia (FiO2 0.14, supine, continuous SpO2 monitoring, SpO2 maintained ≥88%) with serum EPO measured at baseline, 2~h, 4~h, 8~h, 24~h, and 48~h. The outcome metric is EPO AUC over 48~h, with detection threshold defined as less than 60% of age/sex-matched control median.
Mechanistic rationale. If HIF pathway inertia is a core feature of ME/CFS, the EPO response to a controlled hypoxic stimulus should be blunted relative to controls while basal EPO remains normal — a pattern consistent with impaired inducibility rather than absolute HIF deficiency.
Testable prediction. AUC of EPO response over 48~h is ≥40% lower in ME/CFS vs age/sex-matched healthy controls. Abnormal test (>2 SD below control mean) identifies a HIF-inert ME/CFS subtype with distinct clinical features (worse orthostatic intolerance, lower CBFv, steeper PEM gradient).